Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022

Date: October 5, 2017
Pages: 269
Price:
US$ 7,150.00
License [?]:
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G4B61763966EN
Leaflet:

Download PDF Leaflet

Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022
“Global cancer biomarkers market projected to grow at CAGR of 12.2%”

The global cancer biomarkers market is projected to reach USD 20.48 billion by 2022 from USD 11.53 billion in 2017, at a CAGR of 12.2% from 2017 to 2022.

Over the years, the cancer biomarkers market has evolved significantly owing to the rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, and rising demand for personalized medicine in cancer therapies. However, an unfavorable regulatory and reimbursement scenario and the high capital investments required for biomarker development and validation are some factors expected to restrain the market.

“The lung cancer segment is expected to register the highest CAGR’

The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin’s lymphoma, kidney, and other cancers. The lung cancer segment is expected to register the highest CAGR during the forecast period. The increasing company focus on research on lung cancer biomarkers is the key driver for this market. Increased understanding of the morphology of lung carcinogenesis, development of the high-throughput techniques for biomarker discovery, and increased focus on early detection of cancer are propelling the growth of this market.

“North America is expected to dominate the cancer biomarkers market and APAC growing at the highest CAGR”

North America (comprising the US and Canada) is expected to account for the largest share of the global cancer biomarkers market in 2017. The large share of this geographic segment is mainly attributed to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region. While the APAC region is expected to register the highest CAGR during the forecast period. The APAC cancer biomarkers market, particularly in China, Japan, and India is expected to witness high growth during the forecast period.

Break of primary participants was as mentioned below:
  • By Company Type – Tier 1–40%, Tier 2–30%, and Tier 3–30%
  • By Designation – Director level–18%, C-Level–27%, and Others–55%
  • By Region – North America–50%, Europe–20%, Asia-Pacific–20%, and RoW–10%
Major players in this market that are profiled in the report includes Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson (US), Hologic (US), Danaher (US), and Shimadzu (Japan).

Research Coverage:

From an insight perspective, this research report focuses on qualitative data, market size, and growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and challenges). The report also offers market sizes and data on the growth of various segments of the industry. It focuses on emerging and high-growth segments, and high-growth regions. The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on key players in the cancer biomarkers market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output to remain successful.

Reasons to buy this report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.

The report provides insights on the following pointers:
  • Market Penetration: Comprehensive information on products offered by the top players in the cancer biomarkers market
  • Product/Service Enhancement/Innovation: Detailed insights on the upcoming technologies, research & development activities, and new product launches in the cancer biomarkers market
  • Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for profiling technologies across various regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the cancer biomarkers market
  • Competitive Assessment: In-depth assessment of market ranking, strategies, products, and manufacturing capabilities of the leading players in the cancer biomarkers market
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
  1.2.1 MARKETS COVERED
  1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 MARKET SIZE ESTIMATION
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION
  2.2.1 SECONDARY SOURCES
    2.2.1.1 Key Industry Insights
2.3 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 CANCER BIOMARKERS: MARKET SNAPSHOT
4.2 ASIA PACIFIC CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY AND APPLICATION
4.3 CANCER BIOMARKERS MARKET SHARE, BY CANCER TYPE, 2017 VS. 2022
4.4 CANCER BIOMARKERS MARKET SHARE, BY BIOMARKER TYPE, 2015 TO 2022
4.5 CANCER BIOMARKERS MARKET, BY REGION

5 MARKET OVERVIEW

5.1 INTRODUCTION
  5.1.1 DRIVERS
    5.1.1.1 Technological advancements
    5.1.1.2 Rising incidence of cancer
    5.1.1.3 Increasing use of cancer biomarkers in drug discovery and development
    5.1.1.4 Increasing research on cancer biomarkers
  5.1.2 RESTRAINTS
    5.1.2.1 Unfavorable regulatory and reimbursement scenario
    5.1.2.2 High capital investment and low benefit-cost ratio
    5.1.2.3 Technical issues related to sample collection and storage
  5.1.3 OPPORTUNITIES
    5.1.3.1 Personalized medicine
    5.1.3.2 Companion diagnostics
    5.1.3.3 Emerging economies
  5.1.4 CHALLENGES
    5.1.4.1 Proving the clinical validity and utility of biomarker-based tests

6 CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE

6.1 INTRODUCTION
6.2 PROTEIN BIOMARKERS
6.3 GENETIC BIOMARKERS
  6.3.1 LUNG CANCER
  6.3.2 COLORECTAL CANCER
  6.3.3 BREAST CANCER
  6.3.4 PROSTATE CANCER
  6.3.5 LEUKEMIA
6.4 OTHER CANCER BIOMARKERS

7 CANCER BIOMARKER MARKET, BY CANCER TYPE

7.1 INTRODUCTION
7.2 BREAST CANCER
7.3 LUNG CANCER
7.4 COLORECTAL CANCER
7.5 PROSTATE CANCER
7.6 NON-HODGKIN’S LYMPHOMA
7.7 MELANOMA
7.8 LEUKEMIA
7.9 THYROID CANCER
7.10 BLADDER CANCER
7.11 KIDNEY CANCER
7.12 OTHER CANCER TYPES

8 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY

8.1 INTRODUCTION
  8.1.1 OMICS TECHNOLOGIES
  8.1.2 PROTEOMICS
  8.1.3 GENOMICS
    8.1.3.1 Next-generation sequencing (NGS)
    8.1.3.2 Polymerase chain reaction (PCR)
  8.1.4 OTHER OMICS TECHNOLOGIES
8.2 IMAGING TECHNOLOGIES
  8.2.1 ULTRASOUND
  8.2.2 COMPUTED TOMOGRAPHY (CT)
  8.2.3 MAGNETIC RESONANCE IMAGING (MRI)
  8.2.4 POSITRON EMISSION TOMOGRAPHY (PET)
  8.2.5 MAMMOGRAPHY
8.3 IMMUNOASSAYS
8.4 CYTOGENETICS
  8.4.1 IN SITU HYBRIDIZATION (ISH)
  8.4.2 OTHER CYTOGENETICS-BASED TESTS
8.5 BIOINFORMATICS

9 CANCER BIOMARKERS MARKET, BY APPLICATION

9.1 INTRODUCTION
9.2 DIAGNOSTICS
9.3 RESEARCH AND DEVELOPMENT
9.4 PROGNOSTICS
9.5 RISK ASSESSMENT
9.6 OTHER APPLICATIONS

10 CANCER BIOMARKERS MARKET, BY REGION

10.1 INTRODUCTION
10.2 NORTH AMERICA
  10.2.1 US
  10.2.2 CANADA
10.3 EUROPE
  10.3.1 GERMANY
  10.3.2 UK
  10.3.3 FRANCE
  10.3.4 ITALY
  10.3.5 SPAIN
  10.3.6 REST OF EUROPE (ROE)
10.4 ASIA PACIFIC
  10.4.1 JAPAN
  10.4.2 REST OF APAC
10.5 REST OF THE WORLD (ROW)

11 COMPETITIVE LANDSCAPE

11.1 MARKET RANKING ANALYSIS, 2016

12 COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS OFFERED, STRENGTH OF PRODUCT PORTFOLIO, BUSINESS STRATEGY EXCELLENCE, RECENT DEVELOPMENTS.)*

12.1 THERMO FISHER SCIENTIFIC
12.2 BIO-RAD LABORATORIES
12.3 ROCHE DIAGNOSTICS
12.4 QIAGEN N.V.
12.5 ILLUMINA
12.6 GE HEALTHCARE
12.7 AGILENT TECHNOLOGIES
12.8 BIOMÉRIEUX SA
12.9 MERCK & CO.
12.10 ABBOTT LABORATORIES
12.11 BECTON, DICKINSON AND COMPANY
12.12 DANAHER CORPORATION
12.13 MYRIAD GENETICS
12.14 SYSMEX CORPORATION
12.15 HOLOGIC
12.16 QUEST DIAGNOSTICS

*Details on Business Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments, Key relationships might not be captured in case of unlisted companies.

13 APPENDIX

13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.5 AVAILABLE CUSTOMIZATIONS
13.6 RELATED REPORTS
13.7 AUTHOR DETAILS

LIST OF TABLES

Table 1 CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015–2022 (USD MILLION)
Table 2 GLOBAL PROTEIN CANCER BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 3 NORTH AMERICA: PROTEIN CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 4 EUROPE: PROTEIN CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
Table 5 ASIA PACIFIC: PROTEIN CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
Table 6 GLOBAL GENETIC CANCER BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 7 NORTH AMERICA: GENETIC CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 8 EUROPE: GENETIC CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
Table 9 ASIA PACIFIC: GENETIC CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
Table 10 GLOBAL OTHER CANCER BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 11 NORTH AMERICA: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 12 EUROPE: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
Table 13 ASIA PACIFIC: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
Table 14 GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 15 GLOBAL BREAST CANCER BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 16 NORTH AMERICA: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 17 EUROPE: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 18 ASIA PACIFIC: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 19 GLOBAL LUNG CANCER BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 20 NORTH AMERICA: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 21 EUROPE: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 22 ASIA PACIFIC: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 23 GLOBAL COLORECTAL CANCER BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 24 NORTH AMERICA: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 25 EUROPE: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 26 ASIA PACIFIC: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 27 GLOBAL PROSTATE CANCER BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 28 NORTH AMERICA: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 29 EUROPE: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 30 ASIA PACIFIC: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 31 GLOBAL NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 32 NORTH AMERICA: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 33 EUROPE: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 34 ASIA PACIFIC: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 35 GLOBAL MELANOMA BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 36 NORTH AMERICA: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 37 EUROPE: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 38 ASIA PACIFIC: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 39 GLOBAL LEUKEMIA BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 40 NORTH AMERICA: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 41 EUROPE: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 42 ASIA PACIFIC: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 43 GLOBAL THYROID CANCER BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 44 NORTH AMERICA: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 45 EUROPE: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 46 ASIA PACIFIC: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 47 GLOBAL BLADDER CANCER BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 48 NORTH AMERICA: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 49 EUROPE: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 50 ASIA PACIFIC: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 51 GLOBAL KIDNEY CANCER BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 52 NORTH AMERICA: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 53 EUROPE: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 54 ASIA PACIFIC: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 55 GLOBAL OTHER CANCER BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 56 NORTH AMERICA: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 57 EUROPE: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 58 ASIA PACIFIC: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 59 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 60 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2015–2022 (USD MILLION)
Table 61 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY REGION, 2015–2022 (USD MILLION)
Table 62 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 63 EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 64 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 65 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2015–2022 (USD MILLION)
Table 66 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 67 EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 68 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 69 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2015–2022 (USD MILLION)
Table 70 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2015–2022 (USD MILLION)
Table 71 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 72 EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 73 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 74 CANCER BIOMARKERS MARKET FOR NGS, BY REGION, 2015–2022 (USD MILLION)
Table 75 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR NGS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 76 EUROPE: CANCER BIOMARKERS MARKET FOR NGS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 77 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR NGS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 78 CANCER BIOMARKERS MARKET FOR PCR, BY REGION, 2015–2022 (USD MILLION)
Table 79 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PCR, BY COUNTRY, 2015–2022 (USD MILLION)
Table 80 EUROPE: CANCER BIOMARKERS MARKET FOR PCR, BY COUNTRY, 2015–2022 (USD MILLION)
Table 81 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PCR, BY COUNTRY, 2015–2022 (USD MILLION)
Table 82 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2015–2022 (USD MILLION)
Table 83 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 84 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 85 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 86 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2015–2022 (USD MILLION)
Table 87 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2015–2022 (USD MILLION)
Table 88 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 89 EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY/REGION, 2015–2022 (USD MILLION)
Table 90 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 91 CANCER BIOMARKERS MARKET FOR ULTRASOUND, BY REGION, 2015–2022 (USD MILLION)
Table 92 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR ULTRASOUND, BY COUNTRY, 2015–2022 (USD MILLION)
Table 93 EUROPE: CANCER BIOMARKERS MARKET FOR ULTRASOUND, BY COUNTRY, 2015–2022 (USD MILLION)
Table 94 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR ULTRASOUND, BY COUNTRY, 2015–2022 (USD MILLION)
Table 95 CANCER BIOMARKERS MARKET FOR CT, BY REGION, 2015–2022 (USD MILLION)
Table 96 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR CT, BY COUNTRY, 2015–2022 (USD MILLION)
Table 97 EUROPE: CANCER BIOMARKERS MARKET FOR CT, BY COUNTRY, 2015–2022 (USD MILLION)
Table 98 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR CT, BY COUNTRY, 2015–2022 (USD MILLION)
Table 99 CANCER BIOMARKERS MARKET FOR MRI, BY REGION, 2015–2022 (USD MILLION)
Table 100 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR MRI, BY COUNTRY, 2015–2022 (USD MILLION)
Table 101 EUROPE: CANCER BIOMARKERS MARKET FOR MRI, BY COUNTRY, 2015–2022 (USD MILLION)
Table 102 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR MRI, BY COUNTRY, 2015–2022 (USD MILLION)
Table 103 CANCER BIOMARKERS MARKET FOR PET, BY REGION, 2015–2022 (USD MILLION)
Table 104 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 105 EUROPE: CANCER BIOMARKERS MARKET FOR PET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 106 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 107 CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY REGION, 2015–2022 (USD MILLION)
Table 108 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY COUNTRY, 2015–2022 (USD MILLION)
Table 109 EUROPE: CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY COUNTRY, 2015–2022 (USD MILLION)
Table 110 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY COUNTRY, 2015–2022 (USD MILLION)
Table 111 CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2015–2022 (USD MILLION)
Table 112 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 113 EUROPE: CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 114 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 115 CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY REGION, 2015–2022 (USD MILLION)
Table 116 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 117 EUROPE: CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 118 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 119 CANCER BIOMARKERS MARKET FOR ISH, BY REGION, 2015–2022 (USD MILLION)
Table 120 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR ISH, BY COUNTRY, 2015–2022 (USD MILLION)
Table 121 EUROPE: CANCER BIOMARKERS MARKET FOR ISH, BY COUNTRY, 2015–2022 (USD MILLION)
Table 122 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR ISH, BY COUNTRY, 2015–2022 (USD MILLION)
Table 123 CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY REGION, 2015–2022 (USD MILLION)
Table 124 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 125 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 126 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 127 GLOBAL CANCER BIOMARKERS MARKET FOR BIOINFORMATICS, BY REGION, 2015–2022 (USD MILLION)
Table 128 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR BIOINFORMATICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 129 EUROPE: CANCER BIOMARKERS MARKET FOR BIOINFORMATICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 130 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR BIOINFORMATICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 131 GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 132 GLOBAL CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2015–2022 (USD MILLION)
Table 133 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 134 EUROPE: CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 135 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 136 GLOBAL CANCER BIOMARKERS MARKET FOR RESEARCH AND DEVELOPMENT, BY REGION, 2015–2022 (USD MILLION)
Table 137 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR RESEARCH AND DEVELOPMENT, BY COUNTRY, 2015–2022 (USD MILLION)
Table 138 EUROPE: CANCER BIOMARKERS MARKET FOR RESEARCH AND DEVELOPMENT, BY COUNTRY, 2015–2022 (USD MILLION)
Table 139 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR RESEARCH AND DEVELOPMENT, BY COUNTRY, 2015–2022 (USD MILLION)
Table 140 GLOBAL CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY REGION, 2015–2022 (USD MILLION)
Table 141 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 142 EUROPE: CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 143 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 144 GLOBAL CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY REGION, 2015–2022 (USD MILLION)
Table 145 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY COUNTRY, 2015–2022 (USD MILLION)
Table 146 EUROPE: CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY COUNTRY, 2015–2022 (USD MILLION)
Table 147 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY COUNTRY, 2015–2022 (USD MILLION)
Table 148 GLOBAL CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2015–2022 (USD MILLION)
Table 149 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 150 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 151 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 152 GLOBAL CANCER BIOMARKERS MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 153 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 154 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 155 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015–2022 (USD MILLION)
Table 156 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 157 NORTH AMERICA: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 158 NORTH AMERICA: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 159 NORTH AMERICA: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 160 NORTH AMERICA: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 161 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 162 US: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 163 US: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015–2022 (USD MILLION)
Table 164 US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 165 US: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 166 US: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 167 US: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 168 US: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 169 US: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 170 CANADA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 171 CANADA: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015–2022 (USD MILLION)
Table 172 CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 173 CANADA: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 174 CANADA: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 175 CANADA: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 176 CANADA: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 177 CANADA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 178 EUROPE :CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 179 EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 180 EUROPE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015–2022 (USD MILLION)
Table 181 EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 182 EUROPE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 183 EUROPE: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 184 EUROPE: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 185 EUROPE: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 186 EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 187 GERMANY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 188 GERMANY: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015–2022 (USD MILLION)
Table 189 GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 190 GERMANY: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 191 GERMANY: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 192 GERMANY: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 193 GERMANY: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 194 GERMANY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 195 UK: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 196 UK: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015–2022 (USD MILLION)
Table 197 UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 198 UK: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 199 UK: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 200 UK: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 201 UK: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 202 UK: CANCER BIOMARKERS MARKET, BY APPLICATION , 2015–2022 (USD MILLION)
Table 203 FRANCE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 204 FRANCE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015–2022 (USD MILLION)
Table 205 FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 206 FRANCE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 207 FRANCE: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 208 FRANCE: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 209 FRANCE: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 210 FRANCE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 211 ITALY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 212 ITALY: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015–2022 (USD MILLION)
Table 213 ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 214 ITALY: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 215 ITALY: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 216 ITALY: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 217 ITALY: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 218 ITALY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 219 SPAIN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 220 SPAIN: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015–2022 (USD MILLION)
Table 221 SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 222 SPAIN: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 223 SPAIN: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 224 SPAIN: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 225 SPAIN: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 226 SPAIN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 227 ROE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 228 ROE: CANCER BIOMARKERS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 229 ROE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 230 ROE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 231 ROE: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 232 ROE: IMAGING TECHNOLOGIES MARKET, 2015–2022 (USD MILLION)
Table 233 ROE: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 234 ROE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 235 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 236 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 237 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 238 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 239 ASIA PACIFIC: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 240 ASIA PACIFIC: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 241 ASIA PACIFIC: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 242 ASIA PACIFIC: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 243 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 244 JAPAN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 245 JAPAN: CANCER BIOMARKERS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 246 JAPAN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 247 JAPAN: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 248 JAPAN: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 249 JAPAN: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 250 JAPAN: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 251 JAPAN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 252 REST OF APAC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 253 REST OF APAC: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015–2020 (USD MILLION)
Table 254 REST OF APAC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 255 REST OF APAC: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 256 REST OF APAC: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 257 REST OF APAC: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 258 REST OF APAC: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 259 REST OF APAC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 260 ROW: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015–2022 (USD MILLION)
Table 261 ROW: CANCER BIOMARKERS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 262 ROW: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015–2022 (USD MILLION)
Table 263 ROW: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 264 ROW: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 265 ROW: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 266 ROW: CYTOGENETICS MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 267 ROW: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 268 RANK OF COMPANIES IN THE GLOBAL CANCER BIOMARKERS MARKET, 2016

LIST OF FIGURES

Figure 1 RESEARCH DESIGN
Figure 2 BOTTOM-UP APPROACH
Figure 3 TOP-DOWN APPROACH
Figure 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 5 DATA TRIANGULATION
Figure 6 CANCER BIOMARKER MARKET, BY CANCER TYPE, 2017 VS. 2022 (USD MILLION)
Figure 7 CANCER BIOMARKER MARKET, BY BIOMARKER TYPE, 2017 VS. 2022 (USD MILLION)
Figure 8 CANCER BIOMARKER MARKET, BY APPLICATION, 2017 VS. 2022 (USD MILLION)
Figure 9 CANCER BIOMARKER MARKET, BY PROFILING TECHNOLOGY, 2017 VS. 2022 (USD MILLION)
Figure 10 GEOGRAPHICAL SNAPSHOT OF THE CANCER BIOMARKER MARKET
Figure 11 TECHNOLOGICAL ADVANCEMENT IS A MAJOR DRIVER FOR THE CANCER BIOMARKERS MARKET GROWTH IN 2017
Figure 12 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
Figure 13 GENETIC BIOMARKERS TO REGISTER THE HIGHEST CAGR IN THE FORECAST PERIOD
Figure 14 MUTATION RATE OF CELL SURFACE RECEPTOR BIOMARKERS IN BREAST TUMOR
Figure 15 GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE
Figure 16 OMICS TECHNOLOGIES WILL CONTINUE TO DOMINATE THE GLOBAL CANCER BIOMARKERS MARKET IN 2022
Figure 17 DIAGNOSTICS APPLICATION SEGMENT TO DOMINATE THE CANCER BIOMARKERS MARKET IN 2017
Figure 18 CANCER BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT (2017–2022)
Figure 19 NORTH AMERICA MARKET SNAPSHOT
Figure 20 EUROPE MARKET SNAPSHOT
Figure 21 ASIA PACIFIC MARKET SNAPSHOT
Figure 22 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2016)
Figure 23 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2016)
Figure 24 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2016)
Figure 25 QIAGEN N.V.: COMPANY SNAPSHOT (2016)
Figure 26 ILLUMINA: COMPANY SNAPSHOT (2016)
Figure 27 GE HEALTHCARE: COMPANY SNAPSHOT (2016)
Figure 28 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2016)
Figure 29 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2016)
Figure 30 MERCK & CO.INC.: COMPANY SNAPSHOT (2016)
Figure 31 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2016)
Figure 32 BECTON, DICKINSON AND COMPANY : COMPANY SNAPSHOT (2016)
Figure 33 DANAHER CORPORATION: COMPANY SNAPSHOT (2016)
Figure 34 MYRIAD GENETICS INC.: COMPANY SNAPSHOT (2016)
Figure 35 SYSMEX CORPORATION: COMPANY SNAPSHOT (2016)
Figure 36 HOLOGIC: COMPANY SNAPSHOT (2016)
Figure 37 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2016)
Skip to top


Ask Your Question

Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: